NCT04328844 2026-03-30A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersiOncturaPhase 1 Active not recruiting210 enrolled
NCT05455294 2026-01-28Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsDana-Farber Cancer InstitutePhase 1 Active not recruiting16 enrolled
NCT02530034 2026-01-07Hu8F4 in Treating Patients With Advanced Hematologic MalignanciesM.D. Anderson Cancer CenterPhase 1 Active not recruiting72 enrolled
NCT03912064 2026-01-05A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTDana-Farber Cancer InstitutePhase 1 Active not recruiting25 enrolled 17 charts
NCT03560752 2025-12-10CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic TransplantCity of Hope Medical CenterPhase 1 Active not recruiting34 enrolled 10 charts
NCT04454658 2025-07-16Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With MyelofibrosisAbbViePhase 1 Active not recruiting21 enrolled
NCT04041050 2025-02-14A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmAbbViePhase 1 Active not recruiting85 enrolled